Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) Short term Debt (2021 - 2024)

Updated

Coherus Oncology's Short term Debt was $175 million in Q1 2024.

Analysis

Coherus Oncology (CHRS) Short term Debt (2021 - 2024) Analysis & Trends

  • The Q1 2024 figure marks the lowest quarterly Short term Debt since Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 175.00 Mn
Sep 30, 2021 17.31 Mn
Jun 30, 2021 11.54 Mn
API Access

Coherus Oncology Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=CHRS&period=max&api_key=YOUR_API_KEY